[
  [
    "MK-1026-011",
    "CLL/SLL",
    "Untreated",
    "BTK inhibitor",
    "≥20 years",
    "III",
    "Nemtabrutinib",
    "ibrutina/acalatinib",
    "7",
    "6",
    "1",
    "2",
    "李佳玲/4620"
  ],
  [
    "BGB-16673-303",
    "CLL/SLL",
    "Relapsed/Refractory CLL/SLL \n(Exposed to Covalent BTK Inhibitors)",
    "BTK-targeting chimeric degradation activation compound (CDAC)",
    "≥18 years",
    "III",
    "Catadegbrutinib (BGB-16673)",
    "BR / \nhigh-dose methylprednisolone\n+ rituximab (HDMP+R),",
    "4",
    "1",
    "0",
    "3",
    "李佳玲/4620"
  ],
  [
    "20190360",
    "ALL",
    "untreated",
    "anti-CD19",
    "≥18 years",
    "III",
    "Blinatumomab",
    "GMALL\nHyper-CVAD",
    "4",
    "3",
    "0",
    "1",
    "李佳玲/4620"
  ],
  [
    "D7405C00001",
    "CD19+ B-cell ALL (R/R)",
    "1.≥2 prior Tx\n2. CD19(+)\n3. PH(+)->至少兩線TKI failure or replase\n4. PH(-)->至少兩線systemic therapy failure",
    "anti-CD19/CD3",
    "1. ≥12 years\n2. CD19+",
    "I/ II",
    "AZD0486",
    "",
    "3",
    "0",
    "0",
    "0",
    "吳軒綾/3998"
  ],
  [
    "DSP-5336-101",
    "Phase I: AML(R/R), ALL(R/R)\nPhase II: MLLr/ NPM1m AML",
    "4 cycle HMA/ LDAC or 2 cycle combination therapy failure for refractory group",
    "Menin inhibitor",
    "≥18 years",
    "I/ II",
    "DSP-5336",
    "",
    "3",
    "0",
    "0",
    "0",
    "鄭采涵/3974"
  ],
  [
    "75276617ALE1001",
    "KMT2A-r/ NPM1m AML",
    "Cohort A1: KMT2A-r AML\nCohort A2: NPM1m AML",
    "Menin-KMT2A (MLL1) inhibitor",
    "≥18 years",
    "II",
    "Bleximenib",
    "",
    "2",
    "",
    "2",
    "",
    "李佳玲/4620"
  ],
  [
    "AC220-168",
    "AML",
    "Untreated & FLT3-ITD(-)",
    "class III receptor tyrosine kinases",
    "≥18 years",
    "III",
    "Quizartinib/ Placebo",
    "",
    "4",
    "1",
    "3",
    "",
    "李佳玲/4620"
  ],
  [
    "KER-050-D301",
    "MDS",
    "very low-, low-, intermediate risk MDS",
    "tgf-β ligand",
    "≥18 years",
    "III",
    "Elritercept/ placebo",
    "",
    "",
    "",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "ZE46-0134-0002-US",
    "AML (R/R)",
    "Group 1: FLT3 ITD/TDK mutation\nGroup 2: Spliceosome Mutation (SF3B1, SRSF2, U2AF1, ZRSR2)",
    "FLT3 inhibitors",
    "≥18 years",
    "I",
    "ZE46-0134",
    "",
    "",
    "",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "R1979-ONC-2210\n(Olympia-5)",
    "1. FL G1-3a\n2. MZL",
    "1.R/R\n2.≥1 prior Tx",
    "CD20+CD3 bispecific Ab",
    "III",
    "Odronextamab+ Lenalidomide",
    "R2",
    "3",
    "0",
    "0",
    "3",
    "溫上容/3998"
  ],
  [
    "R1979-HM-2299\n(Olympia-4)",
    "r/r aggressive B-cell lymphoma",
    "1. DLBCL(de novo or transformed indolent NHL, high-grade B with MYC+BCL2 ± BCL6\n2. r/r within 12m from 1st treatment",
    "CD20+CD3 bispecific Ab",
    "III",
    "Odronextamab",
    "R-ICE\nR-DHAP\nR-GDP",
    "3",
    "1",
    "0",
    "2",
    "劉璟穎/6452"
  ],
  [
    "ACE1831-001",
    "NHL",
    "R/R",
    "ACC(CAR-T)",
    "I b/ II",
    "ACE1831",
    "",
    "4",
    "2",
    "1",
    "3",
    "鄭采涵/3974"
  ],
  [
    "M22-003",
    "FL Gr 1, Gr 2, or Gr 3a(CD20+)",
    "newly diagnosed + stage, III or IV disease, or stage II with bulky disease",
    "CD20+CD3 bispecific Ab",
    "III",
    "Epcoritamab+ R2",
    "Arm B: G-CHOP/ R-CHOP/ BR\nArm C: R2",
    "5",
    "4",
    "0",
    "1",
    "鄭采涵/3974"
  ],
  [
    "EZH-302",
    "FL Gr 1, Gr 2, or Gr 3a",
    "≥1 prior Tx",
    "EZH 2 innibitor",
    "III",
    "Tazemetostat+ R2",
    "placebo +R2",
    "6",
    "6",
    "2",
    "2",
    "鄭采涵/3974"
  ],
  [
    "D7400C00006",
    "1. DLBCL\n2. High-grad B cell (MYC+BCL2/BCL6)",
    "1. R/R \n2. ≥2 prior Tx",
    "CD19+CD3 bispecific Ab",
    "I",
    "AZD0486(TNB-486)",
    "",
    "5",
    "3",
    "1",
    "3",
    "鄭采涵/3974"
  ],
  [
    "DR-01-ONC-001",
    "1. Cytotoxic T cell Lymphomas\n2. LGL",
    "≥1 prior Tx",
    "human IgG1 antibody against CD94,",
    "I/II",
    "DR-01",
    "",
    "2",
    "2",
    "2",
    "2",
    "李佳玲/4620"
  ],
  [
    "DZ2022J0004",
    "PTCL\nAITL",
    "≥1 prior Tx",
    "JAK 1",
    "III",
    "Golidicitinib",
    "Pralatrexate(缺藥)\nBelinostat\nGemcitabine\nChidamide",
    "4",
    "3",
    "",
    "1",
    "李佳玲/4620"
  ],
  [
    "D7404C00001\n(SOUNDTRACK-B)",
    "module 1: FL (will be recruiting)\nmodule 2: DLBCL",
    "1. R/R \n2. ≥2 prior Tx",
    "CD19+CD3 bispecific Ab",
    "II",
    "AZD0486",
    "Single-Arm (-)",
    "",
    "2",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "D7401C00001",
    "FL Gr 1, Gr 2, or Gr 3a",
    "newly diagnosed + stage, III or IV disease, or stage II with bulky disease",
    "CD19+CD3 bispecific Ab",
    "III",
    "AZD0486",
    "AZD0486+Rituximab",
    "10",
    "1",
    "1",
    "10",
    "吳宜真/3974"
  ],
  [
    "M22-132\n(名額需問slot)",
    "DLBLC",
    "Newly diagnosed",
    "CD20+CD3 bispecific Ab",
    "I b/ II",
    "Epcoritamab + Polatuzumab +RCHP",
    "",
    "",
    "2",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "R3918-PNH-2021",
    "PNH",
    "Untreat or \nEculizumab stop over 3 m or\nRavulizumab stop over 6 m",
    "C5 inhibitor",
    "III",
    "C5 inhibitor",
    "Eculizumab",
    "",
    "",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "MK3543-007",
    "ET",
    "untreat",
    "LSD1",
    "III",
    "MK3543/Hydroxyurea(placebo)",
    "Hydroxyurea(placebo)/MK3543",
    "",
    "",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "KRT-232-115",
    "MF5",
    "JAK inhibitor naive",
    "MDM2",
    "III",
    "Navtemadlin + Ruxolitinib",
    "Navtemadlin(placebo) + Ruxolitinib",
    "",
    "",
    "",
    "",
    "李佳玲/4620"
  ],
  [
    "CT-P44 3.1",
    "MM",
    "≥1 prior Tx(Including Lenalidomide )",
    "CD38+",
    "III",
    "CT-P44+Lena+Dexa",
    "DRd",
    "10",
    "0",
    "0",
    "10",
    "溫上容/3998"
  ],
  [
    "IM048-022\n(EXCALIBER-Maint))",
    "MM",
    "after ASCT with NDMM",
    "CUL4-CRBN E3-Bite",
    "III",
    "Iberdomide",
    "Lenalidomide",
    "7",
    "2",
    "",
    "",
    "曾睦捷/4620"
  ],
  [
    "DREAMM-10(214828)",
    "MM",
    "1. Newly diagnosed MM\n2. ineligible for ASCT",
    "BCMA",
    "III",
    "belantamab mafodotin+Lena+Dexa",
    "DRd",
    "5",
    "3",
    "1",
    "3",
    "鄭采涵/3974"
  ],
  [
    "C1071005",
    "MM",
    "≥2 prior Tx (Including Lenalidomide and Proteasome Inhibitor )",
    "BCMA-Bite",
    "III",
    "1. Elranatamab\n2. Elranatamab+Dara",
    "",
    "10",
    "3",
    "",
    "",
    "曾睦捷/4620"
  ],
  [
    "87562761MMY1001",
    "MM",
    "RRMM",
    "GPRC5D",
    "I",
    "JNJ-87562761",
    "",
    "1",
    "1",
    "",
    "",
    "曾睦捷/4620"
  ]
]